Dapagliflozin Dosage Recommendations
For glycemic control in type 2 diabetes, start dapagliflozin at 5 mg orally once daily and increase to 10 mg once daily if additional glucose lowering is needed; for heart failure, chronic kidney disease, or other non-glycemic indications, use 10 mg once daily from the start. 1
Dosing by Indication
Type 2 Diabetes (Glycemic Control)
- Starting dose: 5 mg orally once daily 1
- Titration: May increase to 10 mg once daily for additional glycemic control 1
- Timing: Can be taken with or without food, though food reduces peak concentrations by 30-50% without affecting overall efficacy 2
The 5 mg starting dose provides substantial glucose-lowering efficacy with mean HbA1c reductions of 0.7-0.8% from baseline 1, 3. The 10 mg dose offers incrementally greater glycemic benefit, with HbA1c reductions approaching 0.8-1.0% 1. Both doses demonstrate dose-dependent glucosuria (18-62 grams of glucose excreted daily) with sustained 24-hour SGLT2 inhibition 4.
Heart Failure, CKD, and Other Indications
- Recommended dose: 10 mg orally once daily 1
- No titration required for these indications
Pre-Treatment Assessment
Before initiating dapagliflozin:
- Assess renal function (eGFR) 1
- Evaluate volume status and correct any volume depletion 1
- Continue monitoring renal function as clinically indicated 1
Renal Function Considerations
Glycemic Control Indication
The glucose-lowering effect diminishes substantially at eGFR <45 mL/min/1.73 m² 5. However, continue dapagliflozin for cardiovascular and kidney benefits even when eGFR falls below this threshold, until dialysis or transplantation 5.
Dosing Adjustments
- No dose adjustment needed for mild-to-moderate renal impairment when using for cardiovascular/renal protection 5
- See individual product labeling for specific eGFR thresholds for initiation 1
- Contraindicated with eGFR <30 mL/min/1.73 m² (note: this applies to metformin, not dapagliflozin per the guideline) 5
Surgical and Procedural Management
Withhold dapagliflozin for at least 3-4 days prior to major surgery or procedures involving prolonged fasting 1, 5. This mitigates the rare but serious risk of diabetic ketoacidosis, including euglycemic DKA presentations 5.
Alternative Dosing Considerations
While twice-daily dosing (2.5 mg or 5 mg every 12 hours) produces similar 24-hour drug exposure and urinary glucose excretion compared to once-daily dosing 6, 7, once-daily administration is the FDA-approved and guideline-recommended regimen 1. The twice-daily approach was explored primarily for fixed-dose combination development but offers no clinical advantage 7.
Pediatric Dosing (Heart Failure)
For children with heart failure and reduced ejection fraction, weight-based dosing has shown short-term safety 8:
- <10 kg: 0.2 mg/kg/day
- 10 to <20 kg: 2.5 mg/day
- 20 to <30 kg: 5 mg/day
- ≥30 kg: Start 5 mg/day, increase to 10 mg/day after one month
Note: Pediatric use is not FDA-approved; this represents emerging research data only.
Key Safety Considerations
- DKA risk: Discontinue during critical illness, prolonged fasting, or if DKA suspected; implement sick-day planning 5
- Volume depletion: Monitor blood pressure and adjust diuretics as needed, particularly in elderly or volume-depleted patients 5
- Genital mycotic infections: Counsel on hygiene; occurs more frequently than placebo 5
- Fournier gangrene: Rare but requires prompt recognition and treatment 5
The dosing strategy is straightforward: use 5 mg for initial diabetes management with option to increase, or go directly to 10 mg for heart failure and kidney protection, maintaining therapy long-term regardless of glycemic effects once cardiovascular/renal benefits become the primary goal.